PMID- 30999928
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20200625
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Apr 18
TI  - Effect of stem cell transplantation on patients with ischemic heart failure: a 
      systematic review and meta-analysis of randomized controlled trials.
PG  - 125
LID - 10.1186/s13287-019-1214-0 [doi]
LID - 125
AB  - Stem cell transplantation (SCT) has become a promising way to treat ischemic 
      heart failure (IHF). We performed a large-scale meta-analysis of randomized 
      clinical trials to investigate the efficacy and safety of SCT in IHF patients. 
      Randomized controlled trials (RCTs) involving stem cell transplantation for the 
      treatment of IHF were identified by searching the PubMed, EMBASE, SpringerLink, 
      Web of Science, and Cochrane Systematic Review databases as well as from reviews 
      and the reference lists of relevant articles. Fourteen eligible randomized 
      controlled trials were included in this study, for a total of 669 IHF patients, 
      of which 380 patients were treated with SCT. The weighted mean difference (WMD) 
      was calculated for changes in the New York Heart Association (NYHA) class, left 
      ventricular ejection fraction (LVEF), left ventricular end-diastolic and 
      end-systolic volumes (LVEDV and LVESV), and Canadian Cardiovascular Society (CCS) 
      angina grade using a fixed effects model, while relative risk (RR) was used for 
      mortality. Compared with the control group, SCT significantly lowered the NYHA 
      class (MD = - 0.73, 95% CI - 1.32 to - 0.14, P < 0.05), LVESV (MD = - 14.80, 95% 
      CI - 20.88 to - 8.73, P < 0.05), and CCS grade (MD = - 0.81, 95% CI - 1.45 to 
      - 0.17, P < 0.05). Additionally, SCT increased LVEF (MD = 6.55, 95% CI 5.93 to 
      7.16, P < 0.05). However, LVEDV (MD = - 0.33, 95% CI - 1.09 to 0.44, P > 0.05) 
      and mortality (RR = 0.86, 95% CI 0.45 to 1.66, P > 0.05) did not differ between 
      the two groups. This meta-analysis suggests that SCT may contribute to the 
      improvement of LVEF, as well as the reduction of the NYHA class, CCS grade, and 
      LVESV. In addition, SCT does not affect mortality.
FAU - Wang, Yixuan
AU  - Wang Y
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
FAU - Xu, Fen
AU  - Xu F
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
FAU - Ma, Jingwei
AU  - Ma J
AD  - Department of Biochemistry and Molecular Biology, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
FAU - Shi, Jiawei
AU  - Shi J
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
FAU - Chen, Si
AU  - Chen S
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
FAU - Liu, Zongtao
AU  - Liu Z
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
FAU - Liu, Junwei
AU  - Liu J
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China. 
      Junweiliu@hust.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20190418
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Heart Failure/*metabolism/mortality/pathology/*therapy
MH  - Humans
MH  - Myocardial Ischemia/*metabolism/mortality/pathology/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - *Stem Cell Transplantation
PMC - PMC6472092
OTO - NOTNLM
OT  - Ischemic heart failure
OT  - Meta-analysis
OT  - Stem cell transplantation
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR 
      PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2019/04/20 06:00
MHDA- 2020/06/26 06:00
PMCR- 2019/04/18
CRDT- 2019/04/20 06:00
PHST- 2019/04/20 06:00 [entrez]
PHST- 2019/04/20 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2019/04/18 00:00 [pmc-release]
AID - 10.1186/s13287-019-1214-0 [pii]
AID - 1214 [pii]
AID - 10.1186/s13287-019-1214-0 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2019 Apr 18;10(1):125. doi: 10.1186/s13287-019-1214-0.